202 KB26 KB192920262018Jensterle Sever, MojcaKocjan, TomažPreželj, Janezletnik:87številka:9/10str. 453-460ISSN:1318-0347COBISSID_HOST:34021081URN:URN:NBN:SI:doc-E9LANWNMslSlovensko zdravniško društvoZdravniški vestnikbisfosfonatibisphosphonatesglucocorticoidsglukokortikoidiosteoporotic fracturesosteoporozni zlomiStrokovna stališča Združenja endokrinologov Slovenije o obravnavi glukokortikoidne osteoporoze| A position statement of the Slovenian endocrine society on the management of glucocorticoid-induced osteoporosis|Treatment with glucocorticoids is the most common cause of secondary osteoporosis. Glucocorticoid osteoporosis is characterised by a very rapid decline in bone mineral density with a rapid increase in the fracture risk, so at the time of glucocorticoid prescription the patient's risk of fracture should be assessed and advice regarding healthy lifestyle, intake of calcium, vitamin D and protein should be given. If indicated, bone-protective agents are introduced as well to increase bone mineral density and reduce vertebral fractures risk. Bisphosphonates are the first choice, while teriparatide is reserved for patients with higher fracture risk who have already sustained a fractureTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo